According to Jindaway's announcement, the company and its subsidiaries Inner Mongolia Jindaway Pharmaceutical Co., Ltd. and Jindaway Biotechnology Co., Ltd. recently received an invention patent certificate issued by the State Intellectual Property Office. The name of the invention is a chondroitin fermentation production control method, patent number ZL202610019817.6. The date of authorization announcement is September 29, 2026, and the patent period is 20 years. This patent belongs to the field of chondroitin production. It can effectively increase the substrate conversion rate and chondroitin content in fermented products. Its acquisition will not have a significant impact on the company's production and operation, but it is conducive to improving the intellectual property protection system and enhancing core competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.